Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer

Z Chen, M Wang, D Wu, L Zhao… - Journal of Medicinal …, 2024 - ACS Publications
CBP/p300 are critical transcriptional coactivators of the androgen receptor (AR) and are
promising cancer therapeutic targets. Herein, we report the discovery of highly potent …
被引用次数：3 相关文章

Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer

Z Chen, M Wang, D Wu, L Zhao… - Journal of …, 2024 - pubmed.ncbi.nlm.nih.gov
CBP/p300 are critical transcriptional coactivators of the androgen receptor (AR) and are
promising cancer therapeutic targets. Herein, we report the discovery of highly potent …

Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer.

Z Chen, M Wang, D Wu, L Zhao, H Metwally… - Journal of Medicinal …, 2024 - europepmc.org
CBP/p300 are critical transcriptional coactivators of the androgen receptor (AR) and are
promising cancer therapeutic targets. Herein, we report the discovery of highly potent …